| Enzon Pharmaceuticals: Value Investment or Simply Speculation? Bud Labitan submitsEnzon Pharmaceuticals, Inc. (ENZN) is a biopharmaceutical company dedicated to the discovery and development of medicines for patients with cancer and other life-threatening conditions. The Company’s drug development program utilizes several technologies, including its Customized Linker Technology and the Locked Nucleic Acid (LNA) technology.It has three compounds in human clinical development: PEG-SN38, the HIF-1 alpha antagonist and the Survivin antagonist. PEGylation has been used on various pharmaceutical compounds (protein, peptides and antibody/antibody fragments) to improve their performance and deliverability. Through the customized attachment of polyethylene glycol (PEG) to a pharmaceutical compound using a spectrum of stable and releasable linkers, its Customized Linker Technology has the potential to overcome the pharmacologic limitations for a universe of molecules and generate compounds. On January 29, 2010, it completed the sale of its specialty pharmaceutical businesComplete Story » seekingalpha.com |
Abbott Posts Flat Earnings Abbott Labs said its earnings were flat as acquisition costs offset double-digit sales growth. online.wsj.com |
AVANIR Pharmaceuticals F3Q10 (Qtr End 06/30/10) Earnings Call Transcript AVANIR Pharmaceuticals (AVNR)F3Q10 (Qtr End 06/30/10) Earnings CallComplete Story » seekingalpha.com |
BioClinica Responds to Shareholder Letter [Business Wire] - BioClinicaâ„¢, Inc. , a global provider of clinical trial management services, has issued the following statement: us.rd.yahoo.com |
Goldfarb Branham Law Firm Pursuing Potential Shareholder Claims Against Clarient Due to Buyout [Business Wire] - Goldfarb Branham LLP is investigating whether the Clarient, Inc. Board of Directors breached fiduciary duties to shareholders in connection with the proposed acquisition of the company by GE Healthcare. us.rd.yahoo.com |